Amunix Patents

Patent portfolio assigned to Amunix (verified via public assignee records). Immuno-oncology platform company (XTEN / Pro-XTEN masked T-cell engagers); acquired by Sanofi for ~$1B in Dec 2021. Merck and Roche are reported as licensees of Amunix technology (partner relationship). No specific direct competitors confirmed from a fetched page, so competitors left empty. Amunix (Operating/Pharmaceuticals) is a patent assignee (XTEN patents, e.g. US10870874B2, US9926351B2).